A higher 600 mg daily dose of FT-4202, a potential disease-modifying oral treatment for sickle cell disease (SCD), was well-tolerated and safe, and improved several measures of red blood cell health after 14 days of treatment, according to…
The opioid crisis, along with the stigma of suspected drug use, and racial bias all contribute to make treatment access more difficult for people with sickle cell disease (SCD). That was the take-home message of the…
A new consortium has been launched by the Critical Path Institute (C-Path) to support the development of safe and effective treatments for people with sickle cell disease. Called the Critical Path for Sickle Cell Disease (CP-SCD), the…
The Scottish Medicines Consortium (SMC) has approved the use of Xromi (hydroxycarbamide), a liquid form of hydroxyurea, for treating children with sickle cell disease (SCD). Xromi is expected to be used in children older than 2 and younger than 9 who…
Pediatric patients with sickle cell disease complicated by acute kidney injury (AKI) were more likely to be admitted to the intensive care unit (ICU), had longer hospital stays, accumulated greater hospitalization costs, and had a higher rate of readmission, a large-scale analysis…
Get regular updates to your inbox.